Element Materials Technology (Element) has acquired Nanosyn, a full-service pharmaceuticals contract development and manufacturing organization, significantly strengthening Element’s offering for pharmaceutical and biopharmaceutical customers in North America.
Nanosyn is a leader in drug discovery and small-batch manufacturing of active pharmaceutical ingredients. It has a track record of providing the highest quality services and operates three facilities in the San Francisco Bay Area of approximately 100,000 sq.ft, two of which are FDA registered.
With a team of more than 75 scientists and experts, more than half of whom have a PhD in a scientific discipline, Nanosyn will bolster Element’s breadth of technical services bringing cutting edge innovation and high growth. The team will support pharmaceuticals and biopharmaceuticals customers from early-stage discovery, through clinical trials, formulation, and regulatory approval.
Jo Wetz, Element CEO, said: “This is our fifth acquisition in the life sciences sector this year. Following this growth, it is now the Element Group’s most significant end market, covering pharmaceuticals, medical devices and environmental testing services.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from Pharmaceutical Outsourcing – all delivered right to your inbox!
Sign up now!